ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
⭐️ CURE ⭐️ Recruiting nowThis phase II trial tests whether a planned sequence of targeted therapies can eliminate HER2+ metastatic breast cancer and allow patients to stop treatment. The study enrolls people with stage IV HER2+ breast cancer at diagnosis. Participants receive a series of drug combination…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
New trial aims to outsmart cancer by adjusting chemo doses in real time
Disease control Recruiting nowThis phase 2 trial tests whether giving the chemotherapy drug capecitabine in a flexible, response-based way (adaptive therapy) can better control metastatic ER-positive breast cancer. About 35 adults with advanced, hormone-resistant disease will receive doses that are adjusted b…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a Two-Drug combo outsmart resistant breast cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether adding a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) to elacestrant works better than elacestrant alone for people with advanced ER+/HER2- breast cancer that has already been treated with a CDK4/6 inhibitor. The study will enro…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising drug combo aims to control advanced breast cancer when standard therapy fails
Disease control Recruiting nowThis study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Egg-Freezing showdown: tamoxifen vs letrozole for breast cancer patients
Disease control Recruiting nowThis phase 3 trial tests whether tamoxifen or letrozole works better for preserving fertility in women with estrogen-sensitive breast cancer before starting chemotherapy. About 309 participants will take one of the two drugs during ovarian stimulation to freeze their eggs. The ma…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a second round of radiation save breasts after cancer returns?
Disease control Recruiting nowThis study tests whether giving radiation again after a second lumpectomy is safe for women with a common type of breast cancer (ER+HER2-). About 114 women who had radiation before and whose cancer came back at least 18 months later will receive targeted radiation over 3 weeks. T…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Youssef Zeidan • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New scanner aims to spot breast Cancer's true reach
Diagnosis Recruiting nowThis early study tests a new imaging device that combines two types of breast scans to see how well it detects estrogen-receptor-positive breast cancer. Up to 20 women with newly diagnosed breast cancer will receive an injection of a radioactive tracer and then be scanned. The re…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
New scan could sharpen targeting of breast cancer brain spread
Diagnosis Recruiting nowThis study aims to improve how doctors find and treat breast cancer that has spread to the brain. Twenty adults with ER-positive breast cancer and brain tumors will get an extra PET scan (FES PET/CT) before their standard radiation planning. Researchers will compare this scan wit…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Biomarker-Guided breast cancer trial aims to personalize therapy
Knowledge-focused Recruiting nowThis study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC